OR WAIT null SECS
AstraZeneca announced that the Phase 3 trial of AZD1222 has been resumed following an adverse patient reaction.
Last week, the clinical trial evaluating AstraZeneca’s COVID-19 vaccine candidate AZD1222 was put on hold after a UK participant suffered a serious adverse reaction. The clinical trials, now in Phase 3, have been resumed after independent reviewers deemed it safe to do so.
“AstraZeneca and the University of Oxford, as the trial sponsor, cannot disclose further medical information,” AstraZeneca said in a statement. “All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.”